Notch signaling promotes growth and invasion in uveal melanoma

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 654-665

  Asnaghi, Laura ^a   Ebrahimi, Katayoon B ^a   Schreck, Karisa C ^a   Bar, Eli E ^a   Coonfield, Michael L ^a   Bell, W Robert ^a   Handa, James ^a   Merbs, Shannath L ^a   Harbour, J William ^b   Eberhart, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBF1 PROTEIN; CELL PROTEIN; GAMMA SECRETASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MRK003; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; SHORT HAIRPIN RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL ACTIVITY; CELL INVASION; CELL LINE; CELL STRAIN MEL285; CELL STRAIN MEL290; CELL STRAIN OCM1; CELL STRAIN OCM3; CELL STRAIN OCM8; CELLULAR PARAMETERS; CLONOGENIC GROWTH; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UVEA MELANOMA;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CYCLIC S-OXIDES; ENZYME INHIBITORS; FEMALE; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; THIADIAZOLES; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856545953     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1406     Document Type: Article

References (38)

1. Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol 2008;4: 629-36.
2. Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009;127:989-98.
3. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347:1222-5. (Pubitemid 26131850)
4. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 2010;16:6083-92.
5. Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A, Shields JA. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011;118: 396-401.
6. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-9. (Pubitemid 39372052)
7. Petrausch U, Martus P, Tonnies H, Bechrakis NE, Lenze D, Wansel S, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008;22:997-1007.
8. van Gils W, Lodder EM, Mensink HW, Kiliç E, Naus NC, Brüggenwirth HT, et al. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci 2008; 49:4254-62.
9. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12:461-8.
10. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008;14:951-6. (Pubitemid 351302538)
11. Crosby MB, Yang H, Gao W, Zhang L, Grossniklaus HE. Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. Br J Ophthalmol 2011;95:112-7.
12. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
13. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
14. Tse WK, Eisenhaber B, Ho SH, Ng Q, Eisenhaber F, Jiang YJ. Genomewide loss-of-function analysis of deubiquitylating enzymes for zebrafish development. BMC Genom 2009;10:637.
15. Pierfelice TJ, Schreck KC, Dang L, Asnaghi L, Gaiano N, Eberhart CG. Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res 2011;71:1115-25.
16. Schouwey K, Aydin IT, Radtke F, Beermann F. RBP-Jkappa-dependent Notch signaling enhances retinal pigment epithelial cell proliferation in transgenic mice. Oncogene 2011;30:313-22.
17. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
18. Austin CP, Feldman DE, Ida JA Jr, Cepko CL. Vertebrate retinal ganglion cells are selected from competent progenitors by the action of Notch. Development 1995;121:3637-50.
19. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-52.
20. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 2011;223:262-73.
21. Koch U, Radtke F. Notch signaling in solid tumors. Curr Top Dev Biol 2010;92:411-55.
22. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-93. (Pubitemid 39446911)
23. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen- activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 2006;66: 4182-90.
24. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009;69:5312-20.
25. Folberg R, Kadkol SS, Frenkel S, Valyi-Nagy K, Jager MJ, Pe'er J, et al. Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci 2008;49:4697-701.
26. Gaiano N, Kohtz JD, Turnbull DH, Fishell G. A method for rapid gain-of-function studies in the mouse embryonic nervous system. Nat Neurosci 1999;2:812-9. (Pubitemid 30491174)
27. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72:8463-71. (Pubitemid 28471781)
28. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'neil J, Kim H, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 2007;14:209-19. (Pubitemid 46274429)
29. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 2011;16:6060-70.
30. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66: 7445-52. (Pubitemid 44289197)
31. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5-16.
32. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, et al. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 2011;30: 3036-48.
33. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010;28:17-28.
34. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-82. (Pubitemid 39006547)
35. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004;3: 895-902. (Pubitemid 39199584)
36. Moriyama M, Osawa M, Mak SS, Ohtsuka T, Yamamoto N, Han H, et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol 2006; 173:333-9.
37. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L, et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 2010;70:10340-50.
38. Strizzi L, Hardy KM, Kirsammer GT, Gerami P, Hendrix MJ. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest 2011;91:819-24.